- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 | 2 | GlobeNewswire (USA) | ||
| 18.07. | ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model | 46 | GlobeNewswire (Europe) | Publication showed that IC 100 suppressed retinal microglia activation by interfering with ASC speck formation, attenuating retinal inflammation, abnormal retinal vascularization, and retinal thinning... ► Artikel lesen | |
| 09.07. | ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024 | 2 | GlobeNewswire (USA) | ||
| 21.05. | Peering Into ZyVersa Therapeutics' Recent Short Interest | 2 | Benzinga.com | ||
| 16.05. | ZyVersa Therapeutics GAAP EPS of -$4.53 misses by $0.78 | 2 | Seeking Alpha | ||
| 15.05. | Zyversa Therapeutics Inc reports results for the quarter ended in March - Earnings Summary | - | Reuters | ||
| 15.05. | ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update | 85 | GlobeNewswire (Europe) | Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease planned to begin... ► Artikel lesen | |
| 15.05. | ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | ZyVersa Therapeutics, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 14.05. | ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention | 1 | GlobeNewswire (USA) | ||
| 10.05. | Zyversa Therapeutics Inc expected to post a loss of $3.70 a share - Earnings Preview | 1 | Reuters | ||
| 29.04. | What's Going On With ZyVersa Stock? | 2 | Benzinga.com | ||
| 29.04. | ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease | 1 | GlobeNewswire (USA) | ||
| 25.04. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 17.04. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.04. | ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes | 147 | GlobeNewswire (Europe) | Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data... ► Artikel lesen | |
| 25.03. | ZyVersa Therapeutics GAAP EPS of -$0.29 | 3 | Seeking Alpha | ||
| 25.03. | ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update | 194 | GlobeNewswire (Europe) | Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical program... ► Artikel lesen | |
| 25.03. | ZyVersa Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease | 134 | GlobeNewswire (Europe) | Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,195 | +2,62 % | Biotech Report: Qiagen knapp im Plus, Evotec geben ab | (shareribs.com) Frankfurt / New York 23.07.2024 - Biotech-Aktien zeigen sich im deutschen Handel schwächer. Für Evotec und Biontech geht es abwärts, Qiagen kann sich behaupten. An der Wall Street verliert... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 8,220 | +149,09 % | Pre-market Movers: Windtree Therapeutics, Carbon Revolution, BurgerFi International, Everi Holdings, Nature's Miracle Holding | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.15 A.M. ET).In the Green Windtree Therapeutics, Inc. (WINT) is up over 117%... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,160 | +0,61 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 25,010 | -11,44 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements | Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts... ► Artikel lesen | |
| IMMUNOVANT | 29,100 | +4,68 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 | Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 11,550 | +10,10 % | DelveInsight Business Research, LLP: Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by 2035, Predicts DelveInsight | Key Companies - Akeso, Summit Therapeutics, Zymeworks, BeiGene, Jazz Pharmaceuticals, Merus, Roche | The landscape of bispecifics and trispecifics antibodies is rapidly evolving, driven by advancements in immunotherapy and targeted cancer treatments. Biotech companies are racing to develop... ► Artikel lesen | |
| EVOTEC | 8,680 | -0,23 % | Evotec Aktie: Analysten sehen Wendepunkt trotz Kursrückgang | Die Evotec-Aktie verzeichnete in den letzten Handelstagen einen deutlichen Kursrückgang und notierte zuletzt bei 8,61 Euro. Trotz des aktuellen Abwärtstrends zeigen sich Analysten für die Zukunft optimistisch.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,130 | +7,63 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, July 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 49,950 | +2,65 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results | Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept... ► Artikel lesen | |
| BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
| KINIKSA PHARMACEUTICALS | 26,120 | +0,81 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $405 - $415 million -- Abiprubart... ► Artikel lesen | |
| CG ONCOLOGY | 33,030 | +0,12 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates | Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)First Patient... ► Artikel lesen | |
| IMMUNOME | 16,510 | +2,99 % | Immunome Reports First Quarter 2024 Financial Results and Provides Business Update | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial... ► Artikel lesen | |
| DYNE THERAPEUTICS | 44,590 | +4,43 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease | WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |
ZYVERSA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,810 Euro und damit -1,04 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZYVERSA THERAPEUTICS INC finden Sie auf Wallstreet Online.
